Top
Turner Syndrome (Premature Ovarian Failure) - Healing Genes
676
post-template-default,single,single-post,postid-676,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Turner Syndrome (Premature Ovarian Failure)

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Rejuvenation of Premature Ovarian Failure With Stem Cells (ROSE-1)

Autologous Stem Cell Therapy for Premature Ovarian Insufficiency and Low Ovarian Reserve


Phase N/A

DESCRIPTION:

The University of Illinois at Chicago is conducting a trial of a treatment for Premature Ovarian Failure (POF) with bone marrow-derived stem cells from the patient’s own body. They are seeking female patients who have a diagnosis of premature ovarian insufficiency who are or would like to achieve pregnancy.

Under anaesthesia, the participants will receive an injection of the stem cells to the right ovary. After treatment, hormone levels, normal menses, and achievement of pregnancy will be followed for 12 months.


PATIENT MUST:

  • Be 18 years of age and older and female
  • Have a diagnosis of premature ovarian insufficiency
  • Meet screening criteria regarding ovarian anatomy
  • Be planning and/or willing to attempt to get pregnant as part of the protocol

THE STUDY INVOLVES:

  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Recovery of the bone marrow aspirate and injection to the right ovary of stem cells isolated from it.
  3. After treatment, hormone levels, normal menses, and achievement of pregnancy will be followed for 12 months.

LOCATIONS AND CONTACTS:

The study site is at the University of Illinois at Chicago. Map.

 

Contacts:

Ashley McHugh  |  312-355-1385  |  [email protected]

Riddhi Vyas  |  312-996-2348  |  [email protected]

 

SPONSOR INFORMATION:

University of Illinois at Chicago

 

Or go online:

https://clinicaltrials.gov/ct2/show/NCT03271229

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader